The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Inner Ear Diseases: Novel Drug Delivery Approaches

  • Lowest Price Guaranteed From USD 1,899

  • Published
    November 2014

  • Pages
    179

  • View Count
    3649

Example Insights

  1. More than 40 drugs are in clinical trials for various inner ear diseases through different routes of administration (both direct and indirect); the companies have now started to realize the potential of this market.
  2. Specifically, drugs delivered directly to the inner ear offer sustained release of the drug increasing the overall efficacy. Currently, there are no marketed drugs yet; however, the pipeline is rich with over 20 molecules in various stages of development.
  3. The first batch of drugs for direct inner ear delivery are anticipated to be launched in 2017; post this, we expect the market to grow at a healthy annualized rate of 96.7% during 2017 – 2025.
  4. Auris Medical is the key leading player, with two of its drugs (AM-101 and AM-111) in late stage clinical trial studies. Other examples include Synphora AB, Orbis Biosciences, O-Ray Pharma, Quark Pharma, Otonomy and Sound Pharmaceuticals. Overall, we have identified 12 companies working in this area.
  5. With regards to the cochlear implants, the market is extremely consolidated; in 2013, Cochlear Ltd. captured over 50% of the total market (in terms of number of units sold). We expect the overall market to grow at an annualized rate of 7.49% from 2014-2025.

Overview

A significant proportion of the world’s population is suffering from otologic diseases. Absence of any disease modifying drugs is a big unmet need in the market. The current treatment of inner ear diseases is primarily based on counselling, electric and magnetic nerve stimulations. At the same time, there is a growing off-label use of drugs for symptomatic relief. Cochlear implants, brainstem implants and hearing aids are other commonly available options to the patients to overcome hearing damages. However, these options do suffer from several limitations such as high cost, poor sound quality, and painful surgeries (in case of implants). The widening gap between the demand and supply of drugs is likely to provide a major impetus to the market in the coming decade. The drugs for direct delivery to inner ear are currently under development and, once approved, are likely to gain a major share of the market.

Direct drug delivery to the inner ear is difficult due to the complex labyrinthine structure of the ear. However, with growing advances in technology and the increasing demands for specific drugs, direct inner ear drug delivery has become one of the key focus areas of researchers and companies across the world. The industry and university sponsored research is aimed at improving the current treatment regime and increasing the concentration of the drug in the inner ear for a promising treatment of otologic diseases. Specifically, intratympanic and intracochlear drug delivery routes are being explored by several stakeholders to devise efficient drug delivery strategies.

Cochlear implants (the only robust option currently available for permanent hearing loss) have also garnered increased attention worldwide. There are currently four established players: Cochlear Ltd., MED-EL, Advanced Bionics and Neurelec. However, the market is gradually opening up and newer players such as China‘s Hangzhou Nurotron have made efforts to come up with cost efficient implants. In addition, the industry has witnessed significant technological advancements with the introduction of water proof speech processors, prolonged battery life and compatibility with remote assistant. ‘Bio-Active’ drug eluting cochlear implants are also anticipatedto be available in the market in the near future.

 

Scope of the Report

The ‘Inner Ear Diseases: Novel Drug Delivery Approaches, 2014 - 2025’ report provides an extensive study of the emerging market of drugs and cochlear implants for otologic diseases. The focus of this study is primarily on the drugs targeting inner ear diseases delivered through intratympanic and intracochlear routes; these drugs provide improved retention time, increase patient compliance, lower treatment cost and offer numerous other advantages. The report covers various aspects such as research pipeline (both industry and academia), technological improvements, sales potential and competitive landscape to assess new evolving opportunities. The study also identifies cochlear implants which are currently available in the market. We have provided a competitive spider web analysis to compare the various implants based on technical parameters (electrode length, electrode contact points etc.) and their user friendliness.

One of the key objectives of this report is to understand the current and future state of the recent advances in drugs and devices for inner ear diseases market. This is done by analyzing the following:

  • Drugs for inner ear delivery currently in the pipeline
  • Size of target consumer segments
  • Frequency of drug injections per year
  • Variable price points
  • Surgical intervention rates

In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The base year for the report is 2014. The report provides market forecasts for the period 2014 - 2025. The figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. It offers a high level view on the current scenario of the market of inner ear drugs and devices and the likely mid-long term evolution.

Chapter 3  provides a general overview of inner ear diseases such as tinnitus, sensorineural hearing loss, meniere’s disease, drug induced ototoxicity etc. This section also provides an introduction to the implants (middle ear implants, cochlear implants, brainstem implants) currently available in the market. We have also discussed the various routes of administration of the drug to the inner ear; this includes systemic, intratympanic and intracochlear routes of drug delivery.

Chapter 4  offers an extensive pipeline of all the inner ear drugs that are being developed by a number of companies and academic institutions. We have also covered details of the current treatment regime for various inner ear diseases such as tinnitus, meniere’s diseases and sensorineural hearing loss.

Chapter 5  covers the drugs which are under development for direct inner ear delivery. The pipeline analysis includes information on the phase of development, nature of drugs, targeted indications etc. The chapter also includes detailed profiles of drugs which are currently in clinical trials; covering information on underlying technology, development history, principal features, current status of development and likely future sales potential.

Chapter 6  provides case studies on four affiliated companies (Orbis Biosciences, Autifony Therapeutics, AudioCure and Sensorion Pharmaceuticals) outlining their current focus and unique technology / platform features.

Chapter 7  focuses on cochlear implants. We have included detailed company profiles of the manufacturers of these implants. These profiles cover the company’s product portfolio, financial information, sales of cochlear implants (wherever available), relevant partnerships, manufacturing facilities and respective future outlooks. We have also provided a sales forecast of cochlear implants over the next ten years.

Chapter 8  is a collection of transcripts based on our discussion with some of the upcoming players in the industry such as AudioCure, Orbis Biosciences, Autifony Therapeutics and Sensorion Pharmaceuticals.

Chapter 9  summarizes the overall report. In this chapter, we provide a recap of the key takeaways and a brief description of some of the emerging technologies that are expected to invade the market in future.

Chapters 10 and 11  are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INNER EAR: AN INTRODUCTION
3.1. Chapter Overview
3.2. Structure of the Ear
3.2.1 Outer Ear
3.2.1.1 Auricle
3.2.1.2 Ear Canal
3.2.1.3 Tympanic Membrane
3.2.2 Middle Ear
3.2.3 Inner Ear
3.2.3.1 Semicircular Canal
3.2.3.2 Vestibule
3.2.3.3 Cochlea
3.3. Inner Ear Diseases
3.3.1. Meniere’s Disease
3.3.2. Sensorineural Hearing Loss
3.3.3. Labyrinthitis
3.3.4. Auto-Immune Inner Ear Disease (AIED)
3.3.5. Vestibular Neuritis
3.3.6. Benign Paroxysmal Positional Vertigo (BPPV)
3.3.7. Tinnitus
3.3.8. Ototoxicity
3.3.9. Noise-Induced Hearing Loss
3.4. Inner Ear Drug Delivery
3.4.1. Systemic Drug Delivery
3.4.2. Intratympanic Drug Delivery
3.4.3. Intracochlear Drug Delivery
3.5. Types of Implants
3.5.1. Cochlear Implants
3.5.2. Other Implants
 
4. INNER EAR DRUG DELIVERY: PIPELINE ANALYSIS
4.1. Chapter Overview
4.2. Industry Sponsored Drugs for Inner Ear Diseases
4.2.1. Drugs for Inner Ear Diseases: Distribution by Phase of Development
4.2.2. Drugs for Inner Ear Diseases: Distribution by Indication
4.2.3. Drugs for Inner Ear Diseases: Distribution by Nature of Drug
4.2.4. Drugs for Inner Ear Diseases: Distribution by Route of Administration
4.3. Academic Research on Inner Ear Diseases
4.3.1. Drugs for Inner Ear Diseases
4.3.2. Nanoparticles for Inner Ear Diseases
4.3.3. Gene Therapy/ Stem Cells for Inner Ear Diseases
4.4. Current Treatment Regimen
4.4.1. Tinnitus
4.4.2. Meniere’s Disease
4.4.3. Sensorineural Hearing Loss
 
5. DIRECT DRUG DELIVERY TO INNER EAR: INTRATYMPANIC, INTRACOCHLEAR, TRANSTYMPANIC AND INTRALABYRINTHINE ROUTES OF DELIVERY
5.1. Chapter Overview
5.2. Direct Drug Delivery to Inner Ear: Current Pipeline
5.2.1. Two Drugs in Late Stage Development
5.3. Direct Drug Delivery to Inner Ear: Nature of Drugs
5.4. Direct Drug Delivery to Inner Ear: Targeted Indications
5.5. Direct Drug Delivery to Inner Ear: Route of Delivery
5.6. Direct Drug Delivery to Inner Ear: Sales Forecast, 2014 - 2025
5.6.1. Scope and Forecast Methodology
5.6.2. Overall Market Size and Forecast
 
5.7. Drug Profiles
5.7.1. AM-101, Auris Medical Holding AG
5.7.1.1. Product Specifications
5.7.1.2. History of Development
5.7.1.3. Current Status of Development
5.7.1.3.1. Post Acute Tinnitus
5.7.1.3.2. Acute Tinnitus
5.7.1.4. Phase II Clinical Trial Results
5.7.1.5. Sales Forecast 2014-2025
 
5.7.2. AM-111, Auris Medical Holding AG
5.7.2.1. Product Specifications
5.7.2.2. History of Development
5.7.2.3. Current Status of Development
5.7.2.4. Phase II Clinical Trial Results
5.7.2.5. Sales Forecast, 2014-2025
5.7.3. Latanoprost, Synphora AB
5.7.3.1. Product Specifications
5.7.3.2. Current Status of Development
5.7.3.3. Phase II Clinical Trial Results
5.7.3.4. Sales Forecast, 2014-2025
 
5.7.4. OTO-104, Otonomy
5.7.4.1. Product Specifications
5.7.4.2. History and Current Status of Development
5.7.4.3. Phase II Clinical Trial Results
5.7.4.4. Sales Forecast, 2014-2025
 
5.7.5. CGF166, Novartis and GenVec
5.7.5.1. Product Specifications
5.7.5.2. History and Current Status of Development
5.7.5.3. Preclinical Trial Results
5.7.5.4. Sales Forecast, 2014-2025
 
5.8. Direct Drug Delivery to Inner Ear: Roots Analysis’ Perspective
 
6. CASE STUDIES
6.1. Introduction
6.1.1. Orbis Biosciences
6.1.2. Autifony Therapeutics
6.1.3. AudioCure
6.1.4. Sensorion Pharma
 
7. COCHLEAR IMPLANTS (BIONIC EARS)
7.1. Introduction
7.1.1. History of Cochlear Implants
7.1.2. Working of a Cochlear Implant
7.1.3. Candidacy for a Cochlear Implant
7.2. Cochlear Implants: Current Market Landscape
7.2.1. Comparative Analysis of Cochlear Implants
7.3. Cochlear Implants: Sales Forecast, 2014-2025
7.3.1. Forecast Methodology
7.3.2. Overall Market Size and Forecast
 
7.4. Key Company Profiles
7.4.1. Cochlear Limited
7.4.1.1. Financial Information
7.4.1.2. Cochlear Implants: Historical Sales
7.4.1.3. Product Portfolio: Nucleus 5, 6, Hybrid and Other Implant Systems
7.4.1.4. Partnerships
7.4.1.5. Manufacturing Facility
7.4.1.6. Future Outlook
 
7.4.2. Med-El
7.4.2.1. Product Portfolio: EAS, Maestro, Synchrony and Other Implant Systems
7.4.2.2. Partnerships
7.4.2.3. Manufacturing Facilities
7.4.2.4. Future Outlook
 
7.4.3. Advanced Bionics (Acquired by Sonova Holding Ag)
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. Product Portfolio: HiRes90K and HiRes90K Advantage
7.4.3.4. Partnerships
7.4.3.5. Manufacturing Facilities
7.4.3.6. Future Outlook
 
7.4.4. Neurelec SA (Acquired by William Demant Holding)
7.4.4.1. Financial Information
7.4.4.2. Product Portfolio: Digisonic SP and Digisonic SP Binaural
7.4.4.3. Other Products
7.4.4.4. Partnerships
7.4.4.5. Future Outlook
 
7.4.5. Hangzhou Nurotron Biotechnology
7.4.5.1. Product Portfolio
7.4.5.2. Partnerships
7.4.5.3. Manufacturing Facilities
7.4.5.4. Future Outlook
 
7.5. Competitive Landscape
7.6. Cochlear Implants: Roots Analysis’ Perspective
 
8. INTERVIEW TRANSCRIPTS
8.1. Prof. Hans Rommelspacher, CEO, AudioCure Pharma
8.2. Dr. Laurent Nguyen, CEO, Sensorion Pharma
8.3. Maria Flynn, President and CEO& Nathan Dormer, Director of Formulation Sciences, Orbis Biosciences
8.4. Barbara Domayne-Hayman, Chief Business Officer, Autifony Therapeutics
 
9. CONCLUSION
9.1. Otologic Indications: Drivers for Market Growth
9.2. Intratympanic and Intracochlear Drug Delivery to Play A Key Role in the Future
9.3. Market Landscape will Continue to Evolve
9.4. Emerging Technologies
9.5. Direct Inner Ear Drug Delivery: Overall Opportunity is Big; A Billion Dollar Market Within a Decade
 
10. APPENDIX 1: TABULATED DATA
 
11. APPENDIX 2: LIST OF COMPANIES

List of Figures

Figure 4.1 Industry Sponsored Inner Ear Drugs: Distribution by Phase of Development
Figure 4.2  Industry Sponsored Inner Ear Drugs: Distribution by Target Indication
Figure 4.3  Industry Sponsored Inner Ear Drugs: Distribution by Nature of Drug
Figure 4.4  Industry Sponsored Inner Ear Drugs: Distribution by Route of Administration
Figure 4.5  Academia Sponsored Inner Ear Drugs: Distribution by Route of Administration
Figure 4.6  Academia Sponsored Inner Ear Drugs: Distribution by Target Indication
Figure 5.1  Inner Ear Drug Developers: Number of Drugs Under Development
Figure 5.2  Drugs Directly Delivered Into Inner Ear: Distribution by Phase of Development
Figure 5.3  Drugs Directly Delivered Into Inner Ear: Distribution by Nature of Active Substance
Figure 5.4  Drugs Directly Delivered Into Inner Ear: Distribution by Type of Indication
Figure 5.5 Drugs Directly Delivered Into Inner Ear: Distribution by Route of Administration
Figure 5.6  Inner Ear Direct Drug Delivery Market Forecast, 2014 - 2025: Base Scenario (USD Million)
Figure 5.7  AM-101: Development History
Figure 5.8  AM-101: Sales Forecast, 2014 - 2025: Base Scenario (USD Million)
Figure 5.9  AM-111: Development History
Figure 5.10 AM-111: Sales Forecast, 2014 - 2025: Base Scenario (USD Million)
Figure 5.11  Latanoprost: Sales Forecast, 2014 - 2025: Base Scenario (USD Million)
Figure 5.12  OTO-104: Development History
Figure 5.13  OTO-104: Sales Forecast, 2014 - 2025: Base Scenario (USD Million)
Figure 5.14  CGF166: Development History
Figure 5.15  CGF166: Sales Forecast, 2014 - 2025: Base Scenario (USD Million)
Figure 5.16 Drug Directly Delivered Into Inner Ear: Drivers and Restraints
Figure 7.1  Cochlear Implants: Development History
Figure 7.2  Working of a Cochlear Implant
Figure 7.3  Cochlear Implants: Distribution by Year of Development
Figure 7.4  Cochlear Implants: Comparative Analysis
Figure 7.5  Cochlear Implants: Sales Forecast, 2014 - 2025: Base Scenario (USD Billion)
Figure 7.6  Cochlear Implant Manufacturers: Distribution by Market Share
Figure 7.7  Cochlear Ltd Annual Revenues, 2010-2014 (USD Million)
Figure 7.8  Cochlear Ltd Annual Revenues, 2014: Distribution by Products (USD Million)
Figure 7.9  Cochlear Ltd Annual Revenues: Distribution by Regions (USD Million)
Figure 7.10  Cochlear Ltd: Units of Implants Sold, 2010-2014
Figure 7.11  Number of Cochlear Ltd Implants Implanted Till 2014
Figure 7.12  Nucleus 5 Cochlear Implant: Internal and External Components
Figure 7.13  Sonova Holding Annual Revenues, 2009-2013 (CHF Million)
Figure 7.14  Sonova Holding Annual Revenues, 2013: Distribution by Products (CHF Million)
Figure 7.15  Sonova Holding Cochlear Implant Revenues, 2010-2013 (CHF Million)
Figure 7.16  Sonova Holding Revenues, 2013: Distribution by Operating Regions (CHF Million)
Figure 7.17  William Demant Annual Revenues, 2009-2013 (DKK Million)
Figure 7.18  William Demant Annual Revenues: Distribution by Products, 2013 (DKK Million)
Figure 7.19  Cochlear Implants Market: Drivers and Restraints
Figure 9.1  Direct Inner Ear Drug Delivery Market, 2017, 2021, 2025 (USD Million)

List of Tables

Table 3.1 Middle Ear: Auditory Ossicles
Table 3.2  Examples of Outer, Middle and Inner Ear Diseases
Table 3.3  Inner Ear Drug Delivery Methods
Table 4.1 Drugs for Inner Ear Diseases: Clinical / Preclinical Pipeline
Table 4.2  Drugs for Inner Ear Diseases: Research Pipeline at Universities
Table 4.3  Nanoparticles for Inner Ear Diseases: Research Pipeline at Universities
Table 4.4  Gene Therapies/ Stem Cells for Inner Ear Diseases: Research Pipeline at Universities
Table 5.1  Drugs Directly Delivered Into Inner Ear: Clinical / Pre-clinical Pipeline
Table 5.2  Current Development Phase and Expected Launch Year of Drugs in Clinical Development
Table 5.3  AM-101: Ongoing Phase III Clinical Trials
Table 5.4  AM-111: Completed/ Planned Clinical Trials
Table 5.5  CGF166: Patent Portfolio
Table 5.6  CGF166: Preclinical Trial Studies
Table 6.1  Case Study: Molecules and their Target Indication
Table 7.1  Degree of Hearing Loss
Table 7.2  Cochlear Implants: Comparative Analysis
Table 7.3  Cochlear Ltd: Marketed Cochlear Implants
Table 7.4  MED-EL: Marketed Cochlear Implant Systems
Table 7.5  MED-EL: Marketed Cochlear Implants
Table 7.6  Advanced Bionics: Product Portfolio
Table 7.7  HiRes 90K: Technical Specifications
Table 7.8  Digisonic SP and Digisonic SP Binaural: Technical Specifications
Table 7.9  Competitive Landscape: Implants and Devices
Table 7.10  Models of Hearing Aids
Table 7.11  Hearing Products: Competitive Analysis
Table 10.1  Industry Sponsored Inner Ear Drugs: Distribution by Phase of Development
Table 10.2  Industry Sponsored Inner Ear Drugs: Distribution by Target Indication
Table 10.3  Industry Sponsored Inner Ear Drugs: Distribution by Nature of Drug
Table 10.4  Industry Sponsored Inner Ear Drugs: Distribution by Route of Administration
Table 10.5  Industry Sponsored Inner Ear Drugs: Distribution by Routes of Delivery
Table 10.6  Academic Research Sponsored Inner Ear Drugs: Distribution by Route of Administration
Table 10.7  Academic Research Sponsored Inner Ear Drugs: Distribution by Target Indication
Table 10.8  Inner Ear Drug Developers: Number of Drugs Under Development
Table 10.9  Drugs Directly Delivered Into Inner Ear: Distribution by Phase of Development
Table 10.10  Drugs Directly Delivered Into Inner Ear: Distribution by Nature of Active Substance
Table 10.11  Drugs Directly Delivered Into Inner Ear: Distribution by Type of Indication
Table 10.12  Drugs Directly Delivered Into Inner Ear: Distribution by Route of Administration
Table 10.13  Inner Ear Direct Drug Delivery: Sales Forecast, 2014 – 2025, Base Scenario (USD Million)
Table 10.14  Inner Ear Direct Drug Delivery: Sales Forecast, 2014 – 2025, Conservative Scenario (USD Million)
Table 10.15  Inner Ear Direct Drug Delivery: Sales Forecast, 2014 – 2025, Optimistic Scenario (USD Million)
Table 10.16  AM-101: Sales Forecast, 2014 – 2025, Base Scenario (USD Million)
Table 10.17  AM-101: Sales Forecast, 2014 – 2025, Conservative Scenario (USD Million)
Table 10.18  AM-101: Sales Forecast, 2014 – 2025, Optimistic Scenario (USD Million)
Table 10.19  AM-111: Sales Forecast, 2014 – 2025, Base Scenario (USD Million)
Table 10.20  AM-111: Sales Forecast, 2014 – 2025, Conservative Scenario (USD Million)
Table 10.21  AM-111: Sales Forecast, 2014 – 2025, Optimistic Scenario (USD Million)
Table 10.22  Latanoprost: Sales Forecast, 2014 – 2025, Base Scenario (USD Million)
Table 10.23  Latanoprost: Sales Forecast, 2014 – 2025, Conservative Scenario (USD Million)
Table 10.24  Latanoprost: Sales Forecast, 2014 – 2025, Optimistic Scenario (USD Million)
Table 10.25  OTO-104: Sales Forecast, 2014 – 2025, Base Scenario (USD Million)
Table 10.26  OTO-104: Sales Forecast, 2014 – 2025, Conservative Scenario (USD Million)
Table 10.27  OTO-104: Sales Forecast, 2014 – 2025, Optimistic Scenario (USD Million)
Table 10.28  CGF166: Sales Forecast, 2014 – 2025, Base Scenario (USD Million)
Table 10.29  CGF166: Sales Forecast, 2014 – 2025, Conservative Scenario (USD Million)
Table 10.30  CGF166: Sales Forecast, 2014 – 2025, Optimistic Scenario (USD Million)
Table 10.31  Cochlear Implants: Sales Forecast, 2014 – 2025, Base Scenario (USD Billion)
Table 10.32  Cochlear Implants: Sales Forecast, 2014 - 2025, Conservative Scenario (USD Billion)
Table 10.33  Cochlear Implants: Sales Forecast, 2014 – 2025, Optimistic Scenario (USD Billion)
Table 10.34  Cochlear Implant Manufacturers: Distribution by Market Share
Table 10.35  Cochlear Ltd Annual Revenues, 2010-2014 (USD Million)
Table 10.36  Cochlear Ltd Annual Revenues, 2014: Distribution by Products (USD Million)
Table 10.37  Cochlear Ltd Annual Revenues: Distribution by Regions (USD Million)
Table 10.38  Cochlear Ltd: Units of Implants Sold, 2010-2014 (USD Million)
Table 10.39  Number of Cochlear Ltd Implants Implanted Till 2014
Table 10.40  Sonova Holding Annual Revenues, 2009-2013 (CHF Million)
Table 10.41  Sonova Holding Annual Revenues, 2013: Distribution by Products (CHF Million)
Table 10.42  Sonova Holding Cochlear Implant Revenues, 2010-2013 (CHF Million)
Table 10.43  Sonova Holding Cochlear Implant Revenues, 2013: Distribution by Operating Regions (CHF Million)
Table 10.44  William Demant Annual Revenues, 2009-2013 (DKK Million)
Table 10.45  William Demant Annual Revenues: Distribution by Products, 2013 (DKK Million)
Table 10.46  Direct Inner Ear Drug Delivery Market, 2017, 2021, 2025 (USD Million)

Listed companies

The following companies and organizations have been mentioned in the report.

  1. Acousia Therapeutics
  2. Advanced Bionics
  3. Akloma Bioscience AB
  4. America Tinnitus Association
  5. Atlassian
  6. Audibel
  7. Audina
  8. Audio Controle
  9. AudioCure Pharma
  10. Audion Therapeutics
  11. Auris Medical
  12. Autifony Therapeutics
  13. Beltone
  14. Bionic Ear Institute
  15. Brainsway
  16. Cerbomed
  17. Carl Zeiss NTS GmbH
  18. CharlesdeGiorgio
  19. Chungbuk National University
  20. Cochlear Ltd.
  21. College of Medicine, Seoul, Korea
  22. Connect Hearing
  23. Cornell University
  24. Coselgi
  25. Dicton
  26. Electone
  27. Eli Lilly
  28. Elkon
  29. Emory University School of Medicine
  30. EstimME
  31. Eurion
  32. Flexion Therapeutics
  33. Fudan University
  34. Genentech
  35. General Hearing Instruments
  36. General Pharma
  37. Genetic Therapeutics
  38. GenVec
  39. GN Resound
  40. Google
  41. Government Medical College, Amritsar (India)
  42. GSK
  43. Hangzhou Nurotron
  44. Hansaton
  45. Immune Pharmaceuticals
  46. IN4 Care
  47. Inception 3
  48. Incube labs
  49. Interton
  50. Jichi Medical University
  51. John Hopkins University
  52. Kagoshima University
  53. Korea Otsuka Pharmaceutical
  54. Kyorin Pharmaceuticals
  55. Kyoto University, Japan
  56. Laboratories Servier
  57. Lincoln pharma
  58. Macquarie University
  59. Masaryk University
  60. Mathworks
  61. MED-EL
  62. Medical University of Vienna
  63. MedGenesis
  64. Merz Pharmaceuticals
  65. Micro Tech Hearing Instruments
  66. Microtransponder
  67. Miracle-Ear
  68. National University Boramae Medical Centre
  69. Naval Medical Center San Diego
  70. Neurelec
  71. Neurotherapies Reset
  72. New York Eye and Ear Infirmary
  73. Novartis
  74. NXP Semiconductors
  75. O-Ray Pharma
  76. Orbis Biosciences
  77. Oricula Therapeutics
  78. Oticon Medical
  79. Otologic Therapeutics
  80. Otonomy
  81. Panasonic
  82. Persona Medical
  83. Phafag
  84. Phonak
  85. Quark Pharma
  86. Resound
  87. Rexton
  88. Rion
  89. Roche
  90. Rudolf Magnus Institute of Neuroscience
  91. S3 Group
  92. Sebotek
  93. Sensorion Pharmaceuticals
  94. Seoul National University College of Medicine, Seoul 
  95. Seoul National University Hospital
  96. Siemens
  97. SIU School of Medicine
  98. Solvay Pharmaceuticals
  99. Sonic Innovations
  100. Sonnovation
  101. Sonova Holding
  102. SophonoTron
  103. Sotex
  104. Sound Pharmaceuticals
  105. Southern Illinois University
  106. Stanford University
  107. Starkey
  108. Synphora AB
  109. The Catholic University of Korea
  110. Unitron
  111. Universidad de Valladolid y Consejo Superior de InvestigacionesCientíficas
  112. University at Buffalo
  113. University College of London
  114. University Medical Centre Utrecht
  115. University of Bath
  116. University of Bonn
  117. University of California San Francisco
  118. University of Heidelberg 
  119. University of Innsbruck
  120. University of Kansas
  121. University of Maryland
  122. University of Melbourne
  123. University of Miami
  124. University of Michigan Health System
  125. University of Oklahoma Health Sciences Centre
  126. University of Pennsylvania School of Medicine
  127. University of Tampere
  128. University of Tübingen
  129. University of Veterinary Medicine Vienna, Austria
  130. Versant Ventures
  131. Widex
  132. William Demant Holding
  133. WiserBAN Consortium
  134. Xiangya Hospital of Central South University
  135. XOMA

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com